Core Viewpoint - Baiyunshan (600332) announced plans to issue asset-backed securities (ABS) worth up to 3 billion yuan to enhance liquidity and optimize financial structure [1] Group 1: Company Actions - Baiyunshan's subsidiary, Guangzhou Pharmaceutical Co., Ltd., will act as the originator for the ABS issuance [1] - The ABS will consist of both senior and subordinated securities, with a maximum maturity of 2 years for each issuance [1] Group 2: Financial Strategy - The securitization of accounts receivable is aimed at obtaining financing and maximizing asset liquidity [1] - This financial strategy is expected to effectively revitalize assets and improve the overall operational efficiency of Guangzhou Pharmaceutical [1]

Core Viewpoint - The company Baiyunshan (00874) has announced a plan for Guangzhou Pharmaceutical to engage in accounts receivable asset securitization, aiming to issue asset-backed securities totaling up to RMB 3 billion by December 1, 2025 [1] Group 1: Transaction Details - The board of directors approved the proposal for Guangzhou Pharmaceutical to sell accounts receivable assets to a plan manager, who will also manage the special plan [1] - The plan manager will issue the asset-backed securities in installments over a period of two years, with each installment having a maximum duration of two years [1] - As of the announcement date, no legally binding agreements have been signed for the proposed transaction [1] Group 2: Asset Characteristics - The underlying assets consist of accounts receivable and associated rights arising from sales of pharmaceuticals and medical devices to public secondary hospitals and commercial companies [1] - The assets include both initial and newly generated accounts receivable [1] Group 3: Financial Strategy - The transaction aims to convert accounts receivable into more liquid cash assets, thereby enhancing asset liquidity, broadening financing channels, and optimizing the company's financial structure [1] - Proceeds from the transaction are intended to supplement Guangzhou Pharmaceutical's working capital or replace existing debt [1]

Core Viewpoint - The company Baiyunshan (00874) has announced a plan for Guangzhou Pharmaceutical to engage in accounts receivable asset securitization, aiming to issue asset-backed securities totaling up to RMB 3 billion by December 1, 2025 [1] Group 1: Transaction Details - The board of directors approved the proposal for Guangzhou Pharmaceutical to sell accounts receivable as underlying assets to a plan manager [1] - The plan manager will agree to purchase these underlying assets and manage the special plan for issuing the securities [1] - The issuance will occur in phases over a two-year period, with each phase having a maximum duration of two years [1] Group 2: Purpose and Benefits - The underlying assets consist of accounts receivable from sales of pharmaceuticals and medical devices to public hospitals and commercial companies [1] - This transaction allows Guangzhou Pharmaceutical to convert accounts receivable into more liquid cash assets, thereby enhancing asset liquidity and optimizing financial structure [1] - Proceeds from the transaction are intended to supplement working capital or replace existing debt [1]

Market Performance - The pharmaceutical commercial sector increased by 0.96% on December 1, with Haiwang Biological leading the gains [1] - The Shanghai Composite Index closed at 3914.01, up 0.65%, while the Shenzhen Component Index closed at 13146.72, up 1.25% [1] Individual Stock Performance - Haiwang Biological (code: 000078) saw a significant rise of 10.00%, closing at 3.74 with a trading volume of 5.34 million shares [1] - Other notable gainers included Jiashitang (code: 002462) with a 3.73% increase, Daclin (code: 603233) up 3.45%, and Kaikai Industrial (code: 600272) rising by 3.05% [1] Capital Flow Analysis - The pharmaceutical commercial sector experienced a net outflow of 255 million yuan from institutional investors, while retail investors saw a net inflow of 272 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Detailed Capital Flow for Selected Stocks - Shanghai Pharmaceuticals (code: 601607) had a net inflow of 36.87 million yuan from institutional investors, while it faced a net outflow of 31.01 million yuan from retail investors [3] - Yifeng Pharmacy (code: 603939) showed a net inflow of 14.39 million yuan from institutional investors, indicating positive sentiment despite overall sector outflows [3]

中国经济网12月1日讯11月28日，国家医保局发布法院刑事判决书摘录文章《鞍山市双山医院药剂科主任刘某红受贿案》。刘某红利用担任鞍山市双山医院 及鞍山市中心医院立山院区药剂科主任职务上的便利，在釆购药品、增加釆购业务量等方面为他人提供帮助。 记者检索中国裁判文书网发现，此摘录文章源自《某明红受贿一审刑事判决书》。此判决书显示，辽宁海悦医药有限公司(扬子江药业集团子公司)业务员涉 其中。 根据判决书，2018年10月至2019年1月，被告人某明红利用其担任药剂科主任的职务便利，接受辽宁海悦医药有限公司(扬子江药业集团子公司)业务员黄某 的请托，为黄某代理的药品协调业务等方面提供帮助，并每月在其办公室内，收受黄某所送钱款，共计10.2万元。 ...

每经头条（nbdtoutiao）——"野生"带玩管家出没迪士尼，从日赚上千卷到350元！专家看到的却是500 亿元"陪伴经济"…… 每经AI快讯，浙江震元（SZ 000705，收盘价：9.57元）11月28日晚间发布公告称，公司第十一届董事 会2025年第五次临时会议于2025年11月28日以通讯形式召开。会议审议了《关于修订部分上市公司制度 的议案》等文件。 （记者 曾健辉） 2025年1至6月份，浙江震元的营业收入构成为：商业占比77.73%，工业-医药制造占比22.27%。 截至发稿，浙江震元市值为32亿元。 ...

（编辑 任世碧） 证券日报网讯 11月28日晚间，国药一致发布公告称，公司董事会于近日收到公司副总经理陈常兵先生 的书面辞任报告。陈常兵先生因工作调整原因，申请辞去公司副总经理职务，辞任后仍在公司担任其他 职务。 ...

每经AI快讯，东北制药（SZ 000597，收盘价：5.59元）11月28日晚间发布公告称，公司第十届第八次 董事会会议于2025年11月28日以通讯表决的方式召开。会议审议了《关于会计估计变更的议案》等文 件。 （记者 王晓波） 2025年1至6月份，东北制药的营业收入构成为：医药制造业占比52.0%，医药商业占比46.18%，其他行 业占比1.82%。 截至发稿，东北制药市值为80亿元。 每经头条（nbdtoutiao）——已有75人遇难，1名死者为消防员，还有10名消防员受伤！记者现场直击香 港大埔火灾：燃烧的宏福苑，五级大火的五个谜团 ...

【重药控股22家下属公司补缴税款4430.26万元】11月28日，重药控股（000950.SZ）披露下属22家公司 合计补缴前期所享受的西部大开发企业所得税优惠税款及滞纳金总计4430.26万元。 公告显示，重药控股下属子公司重庆医药新特药品有限公司、重庆医药集团医贸药品有限公司、重庆医 药集团药特分有限责任公司、重庆医药集团医疗器械有限公司、重庆医药（集团）股份有限公司、重庆 医药集团陕西有限公司、重庆医药和平医药新产品有限公司、重庆医药集团（宁夏）有限公司、和平泰 康资阳药业有限责任公司、重庆医药上海药品销售有限责任公司、重庆医药集团铭维医疗器械有限公 司、重庆和平吉隆医疗器械有限公司、重庆医药互诚科技有限公司、重庆医药集团绵阳医药有限公司、 重庆医药集团供应链管理有限公司、重庆医药合川医药有限责任公司、重庆医药西南生物新药有限责任 公司、重药控股（宁夏）医药有限公司、重药控股贵州医疗有限公司、重庆医药集团江津医药有限公 司、重药天泽（重庆）医疗器械有限公司、重庆医药天昊医药有限公司，共计22家单位根据各自主管税 务部门的通知，经自查需补缴前期所享受的西部大开发企业所得税优惠税款及滞纳金总计4430.26 ...

每经头条（nbdtoutiao）——已有75人遇难，1名死者为消防员，还有10名消防员受伤！记者现场直击香 港大埔火灾：燃烧的宏福苑，五级大火的五个谜团 （记者 王晓波） 2025年1至6月份，人民同泰的营业收入构成为：医药商业批发-医疗客户占比57.85%，医药商业批发-商 业客户占比22.14%，医药商业零售占比18.91%，其他占比0.69%，出租固定资产占比0.2%。 截至发稿，人民同泰市值为73亿元。 每经AI快讯，人民同泰（SH 600829，收盘价：12.67元）11月28日晚间发布公告称，公司董事会同意聘 任曲睿女士为公司证券事务代表，协助董事会秘书履行职责，任期与第十一届董事会任期一致。 ...